[Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19]

Recenti Prog Med. 2024 Sep;115(9):399. doi: 10.1701/4334.43179.
[Article in Italian]
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / therapeutic use
  • COVID-19 / prevention & control
  • COVID-19 Drug Treatment*
  • Cytidine / analogs & derivatives
  • Cytidine / therapeutic use
  • Drug Combinations*
  • Hospitalization* / statistics & numerical data
  • Humans
  • Hydroxylamines / therapeutic use
  • Immunocompromised Host*
  • Lactams
  • Leucine / analogs & derivatives
  • Leucine / therapeutic use
  • Nitriles
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Ritonavir* / administration & dosage
  • Ritonavir* / therapeutic use
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use

Substances

  • Ritonavir
  • molnupiravir
  • Antiviral Agents
  • Drug Combinations
  • Cytidine
  • Hydroxylamines
  • nirmatrelvir and ritonavir drug combination
  • Leucine
  • Proline
  • Sulfonamides
  • Lactams
  • Nitriles